Swiss antibody based drug developer Novimmune has appointed Adrian Mills as Chief Business Officer and a member of the Executive Committee. He will lead the company's commercial development activities, as well as business development.
David Slack, Head of Corporate and Business Development, is leaving Novimmune to focus on opportunities outside the company.
Mills brings to the role more than 20 years of experience as a pharmaceutical executive with a particular focus on the commercialisation of orphan drugs.
He has joined Novimmune from GlaxoSmithKline, where he held various strategic and operational positions from 2000 until 2013 in Europe and SE Asia. Most recently he was European Commercial Director for Rare and Critical Diseases.
Prior to GSK, Mills worked in management consulting and investment banking in the life sciences sector.
